Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 6Phase 3 4Phase 2/3 2Phase 1 2

Status

Completed 25Recruiting 13Unknown 12Terminated 9Active not recruiting 7Not yet recruiting 4Withdrawn 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Lymphoid 1

Conditions

Glioblastoma 3Lymphoma, Follicular 1Hypoxia 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 24Oxaliplatin 24Capecitabine 24Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Docetaxel 18Carboplatin 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Specimen Handling 9Pemetrexed 9Radiation 8Injections 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6Trastuzumab 6Topotecan 6Standard of Care 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Temozolomide × Clear all
NCT07452458 2026-05-04

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

NRG Oncology

Phase 3 Not yet recruiting
398 enrolled
CNS

Glioblastoma

NCT06448286 2026-02-19

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

Jonsson Comprehensive Cancer Center

Phase 3 Not yet recruiting
60 enrolled
CNS

Glioblastoma

NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
408 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT06477939 2024-06-27

THREE-GLEES

Institut de cancérologie Strasbourg Europe

Phase 3 Not yet recruiting
554 enrolled
CNS

Hypoxia, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡